{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=25",
    "query": {
      "intervention": "Placebo Saline Infusion",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 906,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T09:31:03.712Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03924414",
      "title": "Trial of Parkinson's And Zoledronic Acid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson Disease",
        "Osteoporosis",
        "Parkinsonism",
        "Parkinson's Disease and Parkinsonism",
        "Atypical Parkinsonism",
        "Progressive Supranuclear Palsy",
        "Multiple System Atrophy",
        "Vascular Parkinsonism",
        "Dementia With Lewy Bodies"
      ],
      "interventions": [
        {
          "name": "Zoledronic Acid 5Mg/Bag 100Ml Inj",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "California Pacific Medical Center Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 2721,
      "start_date": "2019-11-15",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 77,
      "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 58 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03924414"
    },
    {
      "nct_id": "NCT06376916",
      "title": "Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tachycardia Atrial",
        "Atrial Fibrillation",
        "Atrial Flutter With Rapid Ventricular Response"
      ],
      "interventions": [
        {
          "name": "Magnesium Sulfate 2 G",
          "type": "DRUG"
        },
        {
          "name": "Magnesium Sulfate 4 G",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2024-10-07",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 1,
      "location_summary": "Oak Lawn, Illinois",
      "locations": [
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06376916"
    },
    {
      "nct_id": "NCT04944121",
      "title": "Phase 2 Study of RSLV-132 in Subjects With Long COVID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-acute Corona Virus 19 (COVID-19) (Long COVID)"
      ],
      "interventions": [
        {
          "name": "RSLV-132",
          "type": "DRUG"
        },
        {
          "name": "Sodium Chloride 0.9%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Resolve Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 112,
      "start_date": "2021-06-25",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 5,
      "location_summary": "Mobile, Alabama • Coral Gables, Florida • Pompano Beach, Florida + 2 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04944121"
    },
    {
      "nct_id": "NCT01997515",
      "title": "Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain",
        "Obesity",
        "Hypoxia"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 80,
      "start_date": "2013-11",
      "completion_date": "2019-08-22",
      "has_results": true,
      "last_update_posted_date": "2019-10-07",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01997515"
    },
    {
      "nct_id": "NCT01960348",
      "title": "APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis",
        "Amyloidosis, Hereditary",
        "Amyloid Neuropathies, Familial",
        "Familial Amyloid Polyneuropathies",
        "Amyloid Neuropathies",
        "Amyloidosis, Hereditary, Transthyretin-Related"
      ],
      "interventions": [
        {
          "name": "patisiran (ALN-TTR02)",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 225,
      "start_date": "2013-11",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 13,
      "location_summary": "La Mesa, California • Orange, California • Denver, Colorado + 9 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01960348"
    },
    {
      "nct_id": "NCT02609789",
      "title": "A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "JNJ-55920839",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2015-12",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02609789"
    },
    {
      "nct_id": "NCT04348435",
      "title": "A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "HB-adMSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebos",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Hope Biosciences Research Foundation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 53,
      "start_date": "2020-05-14",
      "completion_date": "2021-05-12",
      "has_results": true,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 1,
      "location_summary": "Sugar Land, Texas",
      "locations": [
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04348435"
    },
    {
      "nct_id": "NCT00882050",
      "title": "Intravenous Exenatide (Byetta) During Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Euglycemia",
        "Hypoglycemia",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Exenatide 0.27 ng/kg/min",
          "type": "DRUG"
        },
        {
          "name": "Exenatide 0.41 ng/kg/min",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2009-03",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2022-01-21",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00882050"
    },
    {
      "nct_id": "NCT04518410",
      "title": "ACTIV-2: A Study for Outpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "bamlanivimab 7000mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BRII-196+BRII-198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SNG001",
          "type": "DRUG"
        },
        {
          "name": "Camostat",
          "type": "DRUG"
        },
        {
          "name": "BMS-986414 + BMS-986413",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (3,840 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (10,240 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CASIRIVIMAB + IMDEVIMAB",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 7000mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 700mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BRII-196+BRII-198",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SNG001",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Camostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (low dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BMS-986414 + BMS-986413",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IM)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (high dose)",
          "type": "DRUG"
        },
        {
          "name": "bamlanivimab 700mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4044,
      "start_date": "2020-08-19",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 207,
      "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04518410"
    },
    {
      "nct_id": "NCT05479981",
      "title": "Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "DM1",
        "Muscular Dystrophies",
        "Myotonic Dystrophy",
        "Myotonic Dystrophy 1",
        "Myotonic Disorders",
        "Muscular Disorders, Atrophic",
        "Muscular Diseases",
        "Musculoskeletal Diseases",
        "Neuromuscular Diseases",
        "Nervous System Diseases",
        "Genetic Diseases, Inborn",
        "Heredodegenerative Disorders, Nervous System",
        "Neurodegenerative Diseases"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AOC 1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 37,
      "start_date": "2022-08-04",
      "completion_date": "2025-09-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-15T09:31:03.712Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05479981"
    }
  ]
}